Phibro

Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results

Retrieved on: 
Tuesday, January 16, 2024
Health, Veterinary, Other Health, Interest, PAHC, ID, Phibro, Webcast

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 7, 2024, after the market closes.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 7, 2024, after the market closes.
  • Phibro management will host a conference call and webcast on Thursday, February 8, 2024, at 9:00 AM Eastern Time.
  • Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event.

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Massachusetts General Hospital, VIC, Research, Insurance, Health, Infection, Vaccine, Enzyme, RNA, Department of Defense Serum Repository, Business development, Biofuel, Livestock, Protein, Filoviridae, EDCL, MHCII, Clinical trial, COVID-19, Webcast, Department of Defence, Business, Messenger, SAS, Animal, Phibro, Safety, Negotiation, Microsoft, Hospital, D, Cryptocurrency, Fine chemical, Pharmaceutical industry, Life insurance, C1, Dyadic

Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.

Key Points: 
  • Phase 1 clinical trial, last patient last visit occurred in September, data lock achieved on November 1, 2023 and top-line results are expected in December 2023 with full study report to follow.
  • Interim phase 1 clinical trial safety results are helping to accelerate the adoption of our C1 protein production platform in use for manufacturing human vaccines.
  • In October 2023, the Company received an upfront payment of $0.6 million for product development.
  • The Company is making progress in developing animal-free recombinant serum albumin with initial positive analytical results towards commercialization and prospective licensing opportunities.

Phibro Animal Health Corporation Reiterates Safety of Mecadox® and Intent to Defend its Use for Customers

Retrieved on: 
Tuesday, November 7, 2023
FDA, Health, Veterinary, Science, Genetically modified bacteria, Food, Pig, CVM, History, Salmonella, Veterinary medicine, PAHC, Carbadox, Edible, Tissue, Animal, Phibro, Safety, Hearing, Food and Drug Administration, Federal Register, Pharmaceutical industry

(NASDAQ: PAHC) The Food and Drug Administration (FDA), through its Center for Veterinary Medicine (CVM), has taken two actions regarding Mecadox® (carbadox), a drug marketed by Phibro Animal Health Corporation.

Key Points: 
  • (NASDAQ: PAHC) The Food and Drug Administration (FDA), through its Center for Veterinary Medicine (CVM), has taken two actions regarding Mecadox® (carbadox), a drug marketed by Phibro Animal Health Corporation.
  • In the first action, FDA has provided notice of a Federal Register publication issuing a final order to revoke the approved method for detecting residues of carbadox.
  • Phibro is extremely disappointed in the actions taken by the FDA and believes fully in the safety of Mecadox.
  • Phibro will take appropriate action and next steps to continue to defend swine producers’ ability to use Mecadox to protect the health and welfare of their animals.

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

Retrieved on: 
Tuesday, October 17, 2023
Veterinary, Health, ID, Interest, Webcast, Phibro, PAHC, Broadcasting

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 8, 2023, after the market closes.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 8, 2023, after the market closes.
  • Phibro management will host a conference call and webcast on Thursday, November 9, 2023, at 9:00 AM Eastern Time.
  • Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event.

Phibro Animal Health Corporation Announces Chief Financial Officer Changes

Retrieved on: 
Tuesday, September 5, 2023
Other Health, Consumer, Health, Pets, Veterinary, Knowledge, Interim, Retirement, PAHC, Management, Phibro

Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced that Damian Finio, Phibro’s Chief Financial Officer, has informed the Company that he will resign from his position effective September 29, 2023.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq:PAHC) (“Phibro” or the “Company”) today announced that Damian Finio, Phibro’s Chief Financial Officer, has informed the Company that he will resign from his position effective September 29, 2023.
  • Mr. Johnson will assume the role of interim Chief Financial Officer of the Company effective as of September 30, 2023 until a successor to Mr. Finio is identified.
  • “I want to take this opportunity to recognize and thank Damian for his many contributions during his tenure as Chief Financial Officer of Phibro and wish him success in his future endeavors,” said Jack Bendheim, Phibro’s Chairman, President and Chief Executive Officer.
  • “I am also pleased to announce that Richard G. Johnson, who served as Phibro’s Chief Financial Officer for more than 18 years, and has continued to provide insight and guidance as a Finance Advisor to the Company since 2020, will be filling the role of Interim Chief Financial Officer as we search for a replacement.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, July 31, 2023
Veterinary, Health, Interest, Webcast, PAHC, Phibro, ID, Broadcasting

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2023 financial results on Wednesday, August 30, 2023, after the market closes.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2023 financial results on Wednesday, August 30, 2023, after the market closes.
  • Phibro management will host a conference call and webcast on Thursday, August 31, 2023, at 9:00 AM Eastern Time.
  • Interested parties are invited to listen to the conference call and view the presentation slides by visiting http://investors.pahc.com .
  • Provide the conference ID 3927884
    A replay of the webcast will be available approximately two hours after the conclusion of the live event.

2023 Louisiana Energy Conference to Be Held in New Orleans May 30 – June 1, 2023

Retrieved on: 
Wednesday, May 24, 2023
Bloomberg Television, Saint Motel, Politics, LEC, Phibro, Carbon, Harvard University, The Ritz-Carlton Hotel Company, Wind, Stockholm School of Economics, Institute for Research in Economics and Business Administration, Foreign Service, Rystad Energy, Master of Science, Partnership, ESG, Commodity, Conference, Pareto, Stockholm School (economics), Financial adviser, Nightclub, Energy, Economics, LNG, Gulf of Mexico

NEW ORLEANS, May 24, 2023 (GLOBE NEWSWIRE) -- The 2023 Louisiana Energy Conference (“LEC”) will be held in New Orleans at the Ritz-Carlton, New Orleans at 921 Canal Street May 30 – June 1, 2023.

Key Points: 
  • NEW ORLEANS, May 24, 2023 (GLOBE NEWSWIRE) -- The 2023 Louisiana Energy Conference (“LEC”) will be held in New Orleans at the Ritz-Carlton, New Orleans at 921 Canal Street May 30 – June 1, 2023.
  • LEC will feature a series of 27 panels and presentations that will address key domestic and international industry developments and topics.
  • LEC is pleased to announce that this year’s keynote speaker will be Nadia Martin Wiggen, Partner in Energy and Commodities at Pareto Securities.
  • Nadia advises companies and institutional investors within the commodities space, focusing on energy and security for Pareto Securities.

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, May 10, 2023
Phibro, RBD, Marketing, Public, Enzyme, Biomedical Advanced Research and Development Authority, Fungus, Influenza, Science, Development, Pandemic, Protein, COVID-19 vaccine, Patent, WNV, Rubic Ghasemi-Nobakht, TBEV, Antigen, University of California, Davis, Albumin, Therapy, Fermentation, Research, Infection, Gene expression, Consultant, RVFV, CGMP, Manuscript, Recombinant, Growth, FDA, BARDA, ACE2, Safety, D, Vaccine, DNA, COVID-19, Antibody, CSR, Government, Animal, UC, Webcast, Food, Omicron, Education, SARS-CoV-2, Clinical trial, CHO, Sale, NIIMBL, Health, Pharmaceutical industry, Financial adviser, Cryptocurrency, Fine chemical, Rare-earth element, Video game, EU, African, C1, Dyadic

Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.

Key Points: 
  • Top 5 Pharma – In April 2023, the Company entered a new research collaboration with a top 5 pharmaceutical company to express a vaccine antigen from C1 for human health.
  • In the first quarter of 2023, the Company entered into a new research collaboration with a biotech company for a fully funded proof-of-concept project to express an enzyme for pharmaceutical applications.
  • G&A Expenses: General and administrative expenses for the quarter ended March 31, 2023, decreased by 10.6% to approximately $1,480,000 compared to $1,656,000 for the quarter ended March 31, 2022.
  • Other Income: Other income for the quarter ended March 31, 2023 was from the sale of the equity interest in Alphazyme, LLC.

Phibro Issues Second Environmental, Social and Governance Report

Retrieved on: 
Monday, May 8, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, Veterinarian, Farmer, PAHC, Report, Sustainability accounting, Animal, GRI, Sustainability Accounting Standards Board, Biophysical environment, ESG, Social, Environment, Management, Phibro

We are proud to share our second Environmental, Social and Governance (ESG) Report (the “Report”).

Key Points: 
  • We are proud to share our second Environmental, Social and Governance (ESG) Report (the “Report”).
  • “I am pleased to share our second annual ESG Report and the progress Phibro has made to generate positive change for people, animals, and the planet.
  • For Phibro, ‘Health at the Heart’ is indicative of our longstanding relationships with customers, the agriculture community, and the public.
  • To read Phibro Animal Health Corporation’s 2022 ESG Report, please visit https://www.pahc.com/responsibility .

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Financial Results

Retrieved on: 
Thursday, April 13, 2023
Agriculture, Health, Natural Resources, Veterinary, Interest, Webcast, PAHC, Phibro, ID, Broadcasting

Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 3, 2023, after the market closes.

Key Points: 
  • Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 3, 2023, after the market closes.
  • Phibro management will host a conference call and webcast on Thursday, May 4, 2023, at 9:00 AM Eastern Time.
  • Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event.